Can oral medicine specialists do oral cancer screenings?

What an oral cancer screening is

A clinical oral cancer screening is a systematic visual and tactile examination of the structures of the mouth, lips, throat, and lymph nodes of the head and neck, performed to detect early lesions that may be malignant or potentially malignant. It is the primary tool for early detection of oral cancer in the dental and oral medicine setting. Stage at detection is what drives outcome: oral-cavity cancer found at a localised stage has a 5-year relative survival of about 89%, falling to about 38% once it has spread to distant sites (NCI SEER).¹

A thorough screening includes:

1. Extra-oral examination: inspection and palpation of the face, neck, lymph nodes (submandibular, submental, cervical, supraclavicular), and lips.
2. Intra-oral inspection: lips (inside and out), labial mucosa, buccal mucosa (both sides), tongue dorsum, tongue lateral borders, ventral (under) surface of the tongue, floor of mouth, hard palate, soft palate, oropharynx, gingiva.
3. Palpation: of the tongue, floor of mouth, and any area where a lesion is suspected, to assess for induration (firmness suggesting deeper involvement).
4. Documentation: any clinically significant finding is photographed and recorded.

The examination takes 10–15 minutes when performed systematically. It is generally painless and requires no special equipment beyond good lighting, a mouth mirror, gauze (for grasping the tongue to inspect the lateral borders), and the clinician's hands.

Who benefits most from screening

Risk factors for oral cancer that justify a higher index of suspicion and (in many guidelines) more frequent screening:³

• Tobacco use — smoking (cigarettes, cigars, pipes) and smokeless tobacco (snuff, chewing tobacco) are the strongest modifiable risk factors. Former smokers carry residual risk for years after quitting.
• Significant alcohol use — alcohol and tobacco together multiply risk rather than simply adding it; their combined effect is greater than either alone.
• Betel nut / areca nut use — areca nut is classified by the IARC as a Group 1 (established) human carcinogen, and betel quid with tobacco is also Group 1 (IARC / WHO).⁵ It is a major risk factor in patient populations from South Asia and Southeast Asia.
• Previous oral cancer or potentially malignant lesion — these patients need lifelong surveillance.
• Heavy sun exposure for lip cancer (predominantly outdoor workers).
• HPV infection — predominantly relevant to oropharyngeal cancers at the back of the throat.
• Immunosuppression — including HIV, post-transplant patients on long-term immunosuppression.
• Heavy family history — less established than the modifiable factors but worth noting.
• Age over 40 — most oral cancers occur in this age range, though HPV-associated cancers can occur younger.

A patient with none of these factors still benefits from an opportunistic screening at any routine dental visit, but the absolute yield (probability of detecting something significant) is lower.

What the screening can and cannot do

What it can do:

• Detect visible lesions early.
• Identify potentially malignant disorders — the conditions the WHO Collaborating Centre for Oral Cancer recognises as carrying a raised risk of malignant change, including leukoplakia, erythroplakia, oral submucous fibrosis, and lichen planus — for surveillance and biopsy decisions (WHO consensus, 2021).⁴
• Establish a baseline for comparison at future visits.
• Provide informed reassurance when nothing concerning is found.
• Identify other oral conditions (mucosal disease, salivary gland enlargement, lymphadenopathy) that warrant separate management.

What it cannot do:

• Detect a lesion that is not visible — early cancers that have not yet broken through the mucosal surface, or cancers in inaccessible locations (deep in the oropharynx, in the salivary glands).
• Provide a diagnosis on its own. A suspicious lesion identified at screening needs biopsy for diagnosis.
• Substitute for evaluation of a specific symptom. If you have a persistent lesion or symptom, that warrants examination regardless of when your last screening was.

A Cochrane systematic review (Brocklehurst et al., 2013) found that, in one large randomised trial, visual screening reduced oral-cancer mortality among high-risk tobacco and alcohol users, although the overall evidence base for population-wide screening is limited; it also found no evidence that adjuncts such as toluidine blue, brush biopsy, or fluorescence devices reduce mortality.² This supports targeted screening of high-risk groups, and does not contradict the value of careful clinical examination as part of standard dental and oral medicine practice.

Adjunctive tools

A number of devices and tests have been marketed as adjuncts to clinical examination:

• Toluidine blue staining.
• Autofluorescence devices (VELscope and similar).
• Brush cytology.
• Salivary diagnostic tests for biomarkers.

The evidence for these tools as screening adjuncts is mixed. Some have utility in selected clinical contexts; none has been shown to replace careful clinical examination as the primary screening modality. Most of our screening is by careful visual and tactile examination with good lighting, supplemented by biopsy where the clinical features warrant histopathological diagnosis.

When to have a screening

Reasonable patterns:

• At any routine dental check-up — a screening should be part of every general dental check-up. If your dentist does not appear to do a systematic mucosal examination at your check-ups, ask them to.
• Annually for patients with risk factors — smokers, heavy drinkers, former oral cancer patients, patients with potentially malignant lesions.
• More frequently for patients under surveillance for a specific potentially malignant lesion — interval set by the specialist based on the lesion type and location.
• At any time for evaluation of a specific symptom or sign — do not wait for a scheduled screening if you have a concern.

What happens if something is found

If a screening identifies a lesion that requires further evaluation:

1. Clinical documentation — photograph, description, location.
2. A clinical assessment of whether to monitor in the short term (some lesions resolve with removal of an irritant) or biopsy.
3. If biopsy is indicated — usually performed under local anaesthetic at the practice, takes 10–15 minutes, tissue sent to an oral pathologist for histopathological diagnosis.
4. The result is discussed at a follow-up visit; further management depends on the diagnosis.

Most biopsies of oral lesions return benign or non-cancerous results. The reason for the biopsy is to know for certain rather than to assume. When biopsy returns a result that requires further treatment, prompt referral to the appropriate specialist team is arranged.

What a screening does NOT need

To clear up some common misunderstandings:

• No fasting is required.
• No special preparation.
• No special imaging is routinely required for screening (though imaging may be requested if a specific lesion needs further evaluation).
• No blood test is part of a screening.
• No medication is changed or stopped for the examination.

This article is general educational content. The right screening frequency for your specific risk profile, and the management of any finding, is determined by clinical assessment.